239 related articles for article (PubMed ID: 34767068)
1. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Multiparametric MRI Radiomics-Based Nomogram in Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Two-Center study.
Wang X; Hua H; Han J; Zhong X; Liu J; Chen J
Clin Breast Cancer; 2023 Aug; 23(6):e331-e344. PubMed ID: 37321954
[TBL] [Abstract][Full Text] [Related]
3. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators.
Zhang F; Huang M; Zhou H; Chen K; Jin J; Wu Y; Ying L; Ding X; Su D; Zou D
Ann Surg Oncol; 2019 Nov; 26(12):3912-3919. PubMed ID: 31359285
[TBL] [Abstract][Full Text] [Related]
4. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.
Kim SY; Cho N; Choi Y; Lee SH; Ha SM; Kim ES; Chang JM; Moon WK
Radiology; 2021 May; 299(2):290-300. PubMed ID: 33754824
[TBL] [Abstract][Full Text] [Related]
5. Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Dynamic Contrast-enhanced and Diffusion-weighted MRI.
Zhao R; Lu H; Li YB; Shao ZZ; Ma WJ; Liu PF
Acad Radiol; 2022 Jan; 29 Suppl 1():S155-S163. PubMed ID: 33593702
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
7. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
Musall BC; Abdelhafez AH; Adrada BE; Candelaria RP; Mohamed RMM; Boge M; Le-Petross H; Arribas E; Lane DL; Spak DA; Leung JWT; Hwang KP; Son JB; Elshafeey NA; Mahmoud HS; Wei P; Sun J; Zhang S; White JB; Ravenberg EE; Litton JK; Damodaran S; Thompson AM; Moulder SL; Yang WT; Pagel MD; Rauch GM; Ma J
J Magn Reson Imaging; 2021 Jul; 54(1):251-260. PubMed ID: 33586845
[TBL] [Abstract][Full Text] [Related]
8. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
9. Nomogram based on quantitative dynamic contrast-enhanced magnetic resonance imaging, apparent diffusion coefficient, and clinicopathological features for early prediction of pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy.
He M; Su J; Ruan H; Song Y; Ma M; Xue F
Quant Imaging Med Surg; 2023 Jul; 13(7):4089-4102. PubMed ID: 37456283
[TBL] [Abstract][Full Text] [Related]
10. Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy.
Ma M; Gan L; Liu Y; Jiang Y; Xin L; Liu Y; Qin N; Cheng Y; Liu Q; Xu L; Zhang Y; Wang X; Zhang X; Ye J; Wang X
Eur J Radiol; 2022 Jan; 146():110095. PubMed ID: 34890936
[TBL] [Abstract][Full Text] [Related]
11. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
[TBL] [Abstract][Full Text] [Related]
12. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
[TBL] [Abstract][Full Text] [Related]
13. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
Abdelhafez AH; Musall BC; Adrada BE; Hess K; Son JB; Hwang KP; Candelaria RP; Santiago L; Whitman GJ; Le-Petross HT; Moseley TW; Arribas E; Lane DL; Scoggins ME; Leung JWT; Mahmoud HS; White JB; Ravenberg EE; Litton JK; Valero V; Wei P; Thompson AM; Moulder SL; Pagel MD; Ma J; Yang WT; Rauch GM
Breast Cancer Res Treat; 2021 Jan; 185(1):1-12. PubMed ID: 32920733
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI.
Cao Y; Wang X; Li L; Shi J; Zeng X; Huang Y; Chen H; Jiang F; Yin T; Nickel D; Zhang J
Diagn Interv Imaging; 2023 Dec; 104(12):605-614. PubMed ID: 37543490
[TBL] [Abstract][Full Text] [Related]
16. Radiomic Nomogram for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer: Predictive Value of Staging Contrast-enhanced CT.
Huang X; Mai J; Huang Y; He L; Chen X; Wu X; Li Y; Yang X; Dong M; Huang J; Zhang F; Liang C; Liu Z
Clin Breast Cancer; 2021 Aug; 21(4):e388-e401. PubMed ID: 33451965
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
18. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
[No Abstract] [Full Text] [Related]
19. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI.
Zhou Z; Adrada BE; Candelaria RP; Elshafeey NA; Boge M; Mohamed RM; Pashapoor S; Sun J; Xu Z; Panthi B; Son JB; Guirguis MS; Patel MM; Whitman GJ; Moseley TW; Scoggins ME; White JB; Litton JK; Valero V; Hunt KK; Tripathy D; Yang W; Wei P; Yam C; Pagel MD; Rauch GM; Ma J
Sci Rep; 2023 Jan; 13(1):1171. PubMed ID: 36670144
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI.
Zhang MQ; Liu XP; Du Y; Zha HL; Zha XM; Wang J; Liu XA; Wang SJ; Zou QG; Zhang JL; Li CY
Br J Radiol; 2024 Jan; 97(1153):228-236. PubMed ID: 38263817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
